BTIG Reiterates Buy on Kazia Therapeutics, Maintains $40 Price Target

Kazia Therapeutics Doses First Participant In Its Arm A Of PNOC035 Platform To Evaluate Paxalisib In Combination With Gemcitabine Toi Treat Atypical Teratoid/Rhabdoid Tumor

Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity

BTIG Maintains Buy on Kazia Therapeutics, Raises Price Target to $40

Kazia Therapeutics Reports New Preclinical And Translational Data Showing Lead Asset Paxalisib Reduced Tumor Burden By 52% In MSS/pMMR Colorectal Cancer

Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further ReductionPaxalisib Was Well Tolerated as Monotherapy and